Pharmaceutical giant Bristol-Myers Squibb will become a limited partner in BioMotiv, a Cleveland-based biotech accelerator, to jointly fund new research into therapies in disease areas with unmet medical needs.  “Partnering with an innovative accelerator like BioMotiv strengthens our ability to translate cutting edge, early-stage academic discoveries into new therapies for patients with serious diseases,” Bruce […]

To read the full article

OR